Lipid-based mRNA chimeric antigen receptor T cells for enhanced in vitro antitumor activity
Summary Chimeric antigen receptor (CAR) T cell therapy provides substantial clinical benefits in hematologic malignancies. However, cell engineering using conventional viral vectors is costly, labor intensive, and prone to safety risks, while electroporation-induced cellular damage limits manufacturing scalability. Thi...